Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 87, Issue 2, 2014, Pages 310-317

  Vecchi, S ^a   Bufali, S ^a   Uno, T ^b   Wu, T ^b   Arcidiacono, L ^a   Filippini, S ^a   Rigat, F ^a   O'Hagan, D ^c  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c Vaccines Research   (United States)

Author keywords

Adjuvants; Conjugation; Dose reduction; Immunogenicity; S. pneumoniae; TLR7 agonist

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN RRGB TOLL LIKE RECEPTOR 7 AGONIST CONJUGATE; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; VACCINE; ANTIBODY CONJUGATE; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; MEMBRANE PROTEIN; PNEUMOCOCCUS VACCINE; TLR7 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTEREMIA; CHEMICAL BINDING; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG SCREENING; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MORTALITY; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; AGONISTS; ANIMAL; BACTERIAL LOAD; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; HL 60 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; PHAGOCYTE; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; TIME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL LOAD; DISEASE MODELS, ANIMAL; FEMALE; HL-60 CELLS; HUMANS; IMMUNIZATION; IMMUNOCONJUGATES; MEMBRANE GLYCOPROTEINS; MICE, INBRED BALB C; PHAGOCYTES; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS; TOLL-LIKE RECEPTOR 7;

EID: 84902358526     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.01.002     Document Type: Article

References (43)

1. C.L. Ahonen, C.L. Doxsee, S.M. McGurran, T.R. Riter, W.F. Wade, R.J. Barth, J.P. Vasilakos, R.J. Noelle, and R.M. Kedl Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN J. Exp. Med. 199 2004 775 784
2. O. Arican, F. Guneri, K. Bilgic, and A. Karaoglu Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study J. Dermatol. 31 2004 627 631
3. A. Bardotti, G. Averani, F. Berti, S. Berti, V. Carinci, S. D'Ascenzi, B. Fabbri, S. Giannini, A. Giannozzi, C. Magagnoli, D. Proietti, F. Norelli, R. Rappuoli, S. Ricci, and P. Costantino Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases Vaccine 26 2008 2284 2296
4. M.A. Barocchi, J. Ries, X. Zogaj, C. Hemsley, B. Albiger, A. Kanth, S. Dahlberg, J. Fernebro, M. Moschioni, V. Masignani, K. Hultenby, A.R. Taddei, K. Beiter, F. Wartha, A. von Euler, A. Covacci, D.W. Holden, S. Normark, R. Rappuoli, and B. Henriques-Normark A pneumococcal pilus influences virulence and host inflammatory responses Proc. Natl. Acad. Sci. USA 103 2006 2857 2862
5. J.M. Blander Coupling Toll-like receptor signaling with phagocytosis: potentiation of antigen presentation Trends Immunol. 28 2007 19 25
6. J.M. Blander, and R. Medzhitov Toll-dependent selection of microbial antigens for presentation by dendritic cells Nature 440 2006 808 812
7. D.E. Briles, S.K. Hollingshead, J.C. Paton, E.W. Ades, L. Novak, F.W. van Ginkel, and W.H. Benjamin Jr. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae J. Infect. Dis. 188 2003 339 348
8. M. Chan, T. Hayashi, C.S. Kuy, C.S. Gray, C.C. Wu, M. Corr, W. Wrasidlo, H.B. Cottam, and D.A. Carson Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates Bioconjugate Chem. 20 2009 1194 1200
9. D.H. Dockrell, and G.R. Kinghorn Imiquimod and resiquimod as novel immunomodulators J. Antimicrob. Chemother. 48 2001 751 755
10. L. El Mortaji, C. Contreras-Martel, M. Moschioni, I. Ferlenghi, C. Manzano, T. Vernet, A. Dessen, and A.M. Di Guilmi The full-length Streptococcus pneumoniae major pilin RrgB crystallizes in a fibre-like structure, which presents the D1 isopeptide bond and provides details on the mechanism of pilus polymerization Biochem. J. 441 2012 833 841
11. C. Foged, C. Arigita, A. Sundblad, W. Jiskoot, G. Storm, and S. Frokjaer Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition Vaccine 22 2004 1903 1913
12. M.A. Gentile, S. Melchiorre, C. Emolo, M. Moschioni, C. Gianfaldoni, L. Pancotto, I. Ferlenghi, M. Scarselli, W. Pansegrau, D. Veggi, M. Merola, F. Cantini, P. Ruggiero, L. Banci, and V. Masignani Structural and functional characterization of the Streptococcus pneumoniae RrgB pilus backbone D1 domain J. Biol. Chem. 286 2011 14588 14597
13. C. Gianfaldoni, S. Censini, M. Hilleringmann, M. Moschioni, C. Facciotti, W. Pansegrau, V. Masignani, A. Covacci, R. Rappuoli, M.A. Barocchi, and P. Ruggiero Streptococcus pneumoniae pilus subunits protect mice against lethal challenge Infect. Immun. 75 2007 1059 1062
14. C. Harfouche, S. Filippini, C. Gianfaldoni, P. Ruggiero, M. Moschioni, S. Maccari, L. Pancotto, L. Arcidiacono, B. Galletti, S. Censini, E. Mori, M. Giuliani, C. Facciotti, E. Cartocci, S. Savino, F. Doro, M. Pallaoro, S. Nocadello, G. Mancuso, M. Haston, D. Goldblatt, M.A. Barocchi, M. Pizza, R. Rappuoli, and V. Masignani RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies Infect. Immun. 80 2012 451 460
15. H. Hemmi, T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway Nat. Immunol. 3 2002 196 200
16. M. Hilleringmann, F. Giusti, B.C. Baudner, V. Masignani, A. Covacci, R. Rappuoli, M.A. Barocchi, and I. Ferlenghi Pneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg A PLoS Pathog. 4 2008 e1000026
17. G. Jin, C.C. Wu, R.I. Tawatao, M. Chan, D.A. Carson, and H.B. Cottam Synthesis and immunostimulatory activity of 8-substituted amino 9-benzyladenines as potent Toll-like receptor 7 agonists Bioorg. Med. Chem. Lett. 16 2006 4559 4563
18. D. Johnston, and J.C. Bystryn Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine Vaccine 24 2006 1958 1965
19. D. Johnston, B. Zaidi, and J.C. Bystryn TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines Cancer Immunol. Immunother. 56 2007 1133 1141
20. K. Kastenmuller, U. Wille-Reece, R.W. Lindsay, L.R. Trager, P.A. Darrah, B.J. Flynn, M.R. Becker, M.C. Udey, B.E. Clausen, B.Z. Igyarto, D.H. Kaplan, W. Kastenmuller, R.N. Germain, and R.A. Seder Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets J. Clin. Invest. 121 2011 1782 1796
21. J. LeMieux, D.L. Hava, A. Basset, and A. Camilli RrgA and RrgB are components of a multisubunit pilus encoded by the Streptococcus pneumoniae rlrA pathogenicity islet Infect. Immun. 74 2006 2453 2456
22. R.L. Miller, J.F. Gerster, M.L. Owens, H.B. Slade, and M.A. Tomai Imiquimod applied topically: a novel immune response modifier and new class of drug Int. J. Immunopharmacol. 21 1999 1 14
23. M. Moschioni, G. De Angelis, C. Harfouche, E. Bizzarri, S. Filippini, E. Mori, G. Mancuso, F. Doro, M.A. Barocchi, P. Ruggiero, and V. Masignani Immunization with the RrgB321 fusion protein protects mice against both high and low pilus-expressing Streptococcus pneumoniae populations Vaccine 30 2012 1349 1356
24. D.M. Musher Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment Clin. Infect. Dis. 14 1992 801 807
25. D.M. Musher, H.M. Phan, and R.E. Baughn Protection against bacteremic pneumococcal infection by antibody to pneumolysin J. Infect. Dis. 183 2001 827 830
26. D.T. O'Hagan, and E. De Gregorio The path to a successful vaccine adjuvant - 'the long and winding road' Drug Discov. Today 14 2009 541 551
27. D.T. O'Hagan, and N.M. Valiante Recent advances in the discovery and delivery of vaccine adjuvants Nat. Rev. Drug Discov. 2 2003 727 735
28. J.Z. Oh, and R.M. Kedl The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity J. Immunol. 185 2010 4602 4608
29. C. Othoro, D. Johnston, R. Lee, J. Soverow, J.C. Bystryn, and E. Nardin Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod Infect. Immun. 77 2009 739 748
30. M.O. Oyewumi, A. Kumar, and Z. Cui Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses Expert Rev. Vaccines 9 2010 1095 1107
31. A.S. Rosenberg Effects of protein aggregates: an immunologic perspective AAPS J. 8 2006 E501 E507
32. G. Spraggon, E. Koesema, M. Scarselli, E. Malito, M. Biagini, N. Norais, C. Emolo, M.A. Barocchi, F. Giusti, M. Hilleringmann, R. Rappuoli, S. Lesley, A. Covacci, V. Masignani, and I. Ferlenghi Supramolecular organization of the repetitive backbone unit of the Streptococcus pneumoniae pilus PLoS ONE 5 2010 e10919
33. B.G. Spratt, and B.M. Greenwood Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 356 2000 1210 1211
34. M.A. Stanley Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential Clin. Exp. Dermatol. 27 2002 571 577
35. N. Stephanopoulos, and M.B. Francis Choosing an effective protein bioconjugation strategy Nat. Chem. Biol. 7 2011 876 884
36. D. Tietz, A. Aldroubi, R. Schneerson, M. Unser, and A. Chrambach The distribution of particles characterized by size and free mobility within polydisperse populations of protein-polysaccharide conjugates, determined from two-dimensional agarose electropherograms Electrophoresis 12 1991 46 54
37. M.A. Tomai, and J.P. Vasilakos TLR-7 and -8 agonists as vaccine adjuvants Expert Rev. Vaccines 10 2011 405 407
38. T.D. Tran, D.C. Pryde, P. Jones, F.M. Adam, N. Benson, G. Bish, F. Calo, G. Ciaramella, R. Dixon, J. Duckworth, D.N. Fox, D.A. Hay, J. Hitchin, N. Horscroft, M. Howard, I. Gardner, H.M. Jones, C. Laxton, T. Parkinson, G. Parsons, K. Proctor, M.C. Smith, N. Smith, and A. Thomas Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection Bioorg. Med. Chem. Lett. 21 2011 2389 2393
39. D. Valmori, N.E. Souleimanian, V. Tosello, N. Bhardwaj, S. Adams, D. O'Neill, A. Pavlick, J.B. Escalon, C.M. Cruz, A. Angiulli, F. Angiulli, G. Mears, S.M. Vogel, L. Pan, A.A. Jungbluth, E.W. Hoffmann, R. Venhaus, G. Ritter, L.J. Old, and M. Ayyoub Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming Proc. Natl. Acad. Sci. USA 104 2007 8947 8952
40. S. Vecchi, S. Bufali, D.A. Skibinski, D.T. O'Hagan, and M. Singh Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations J. Pharm. Sci. 101 2012 17 20
41. U. Wille-Reece, B.J. Flynn, K. Lore, R.A. Koup, R.M. Kedl, J.J. Mattapallil, W.R. Weiss, M. Roederer, and R.A. Seder HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates Proc. Natl. Acad. Sci. USA 102 2005 15190 15194
42. U. Wille-Reece, C.Y. Wu, B.J. Flynn, R.M. Kedl, and R.A. Seder Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses J. Immunol. 174 2005 7676 7683
43. C.C. Wu, T. Hayashi, K. Takabayashi, M. Sabet, D.F. Smee, D.D. Guiney, H.B. Cottam, and D.A. Carson Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand Proc. Natl. Acad. Sci. USA 104 2007 3990 3995